» Articles » PMID: 21330907

Safety and Effectiveness of BufferGel and 0.5% PRO2000 Gel for the Prevention of HIV Infection in Women

Abstract

Objective: To determine the safety and effectiveness of BufferGel and 0.5% PRO2000 microbicide gels for the prevention of male-to-female HIV transmission.

Design: Phase II/IIb, randomized, placebo-controlled trial with three double-blinded gel arms and an open-label no gel arm.

Methods: Study participants from Malawi, South Africa, Zambia, Zimbabwe, and the USA were instructed to apply study gel up to 1 h before each sex act and safety, sexual behavior, pregnancy, gel adherence, acceptability, and HIV serostatus were assessed during follow-up.

Results: The 3101 enrolled women were followed for an average of 20.4 months with 93.6% retention and 81.1% self-reported gel adherence. Adverse event rates were similar in all study arms. HIV incidence rates in the 0.5% PRO2000 gel, BufferGel, placebo gel, and no gel arms were 2.70, 4.14, 3.91, and 4.02 per 100 women-years, respectively. HIV incidence in the 0.5% PRO2000 gel arm was lower than the placebo gel arm (hazard ratio = 0.7, P = 0.10) and the no gel arm (hazard ratio = 0.67, P = 0.06). HIV incidence rates were similar in the BufferGel and both placebo gel (hazard ratio = 1.10, P = 0.63) and no gel control arms (hazard ratio = 1.05, P = 0.78). HIV incidence was similar in the placebo gel and no gel arms (hazard ratio = 0.97, P = 0.89).

Conclusion: The 0.5% PRO2000 gel demonstrated a modest 30% reduction in HIV acquisition in women. However, these results were not statistically significant and subsequent findings from the Microbicide Development Programme (MDP) 301 trial have confirmed that 0.5% PRO2000 gel has little or no protective effect. BufferGel did not alter the risk of HIV infection. Both products were well tolerated.

Citing Articles

Review of Impact of Risk Reduction Sessions on Sexual Behaviors in HIV Prevention Trials: Insights from Africa.

Wand H, Reddy T, Moodley J, Naidoo S, Ramjee G Arch Sex Behav. 2025; 54(2):805-815.

PMID: 39806191 DOI: 10.1007/s10508-024-03052-8.


Clinical trial simulation to evaluate tenofovir disoproxil fumarate/emtricitabine HIV pre-exposure prophylaxis dosing during pregnancy.

Scott R, Yu Y, Marzinke M, Coleman J, Hendrix C, Bies R Front Reprod Health. 2023; 5:1224580.

PMID: 37830105 PMC: 10565828. DOI: 10.3389/frph.2023.1224580.


Broadly neutralizing antibodies consistently trap HIV-1 in fresh cervicovaginal mucus from select individuals.

Schaefer A, Yang B, Schroeder H, Harit D, Humphry M, Ravel J Acta Biomater. 2023; 169:387-397.

PMID: 37499728 PMC: 10619885. DOI: 10.1016/j.actbio.2023.07.031.


Spatial variations in STIs among women enrolled in HIV prevention clinical trials in Durban, KwaZulu-Natal, South Africa.

Dassaye R, Wand H, Reddy T, Tanser F, Sartorius B, Morris N SAHARA J. 2023; 20(1):2193238.

PMID: 36995287 PMC: 10064823. DOI: 10.1080/17290376.2023.2193238.


Modeling the Probability of HIV Infection over Time in High-Risk Seronegative Participants Receiving Placebo in Five Randomized Double-Blind Placebo-Controlled HIV Pre-Exposure Prophylaxis Trials: A Patient-Level Pooled Analysis.

Garcia-Cremades M, Hendrix C, Jayachandran P, Strydom N, Jarlsberg L, Grant R Pharmaceutics. 2022; 14(9).

PMID: 36145549 PMC: 9504389. DOI: 10.3390/pharmaceutics14091801.


References
1.
Bentley M, Morrow K, Fullem A, Chesney M, Horton S, Rosenberg Z . Acceptability of a novel vaginal microbicide during a safety trial among low-risk women. Fam Plann Perspect. 2000; 32(4):184-8. View

2.
Elias C, Coggins C . Female-controlled methods to prevent sexual transmission of HIV. AIDS. 1996; 10 Suppl 3:S43-51. View

3.
Connor R . Sensitivity of non-clade B primary HIV-1 isolates to mildly acidic pH. J Acquir Immune Defic Syndr. 2006; 43(4):499-501. DOI: 10.1097/01.qai.0000243048.50451.18. View

4.
Fleming T, Richardson B . Some design issues in trials of microbicides for the prevention of HIV infection. J Infect Dis. 2004; 190(4):666-74. DOI: 10.1086/422603. View

5.
Mayer K, Peipert J, Fleming T, Fullem A, Moench T, Cu-Uvin S . Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States. Clin Infect Dis. 2001; 32(3):476-82. DOI: 10.1086/318496. View